Medindia

X

Hard to Treat Diseases (HTDS) Collagenna Skin Care Products At The Health Pharma Bern Expo

Friday, April 9, 2010 Press Release J E 4
Advertisement
OTTAWA, April 8 /PRNewswire-FirstCall/ - Hard to Treat Diseases (HTDS; http://www.htdsmedical.com/) Collagenna Skin Care Products will be officially presented to the Swiss Pharmaceutical and Health Care Sector at the upcoming Health Pharma Bern Expo April 10/11, 2010. http://www.healthandpharma.ch/

Collagenna Skin Care Products' exclusive distributor Alphaderm Body and Wellness, www.alphaderm.ch will be exhibiting at the show. Collagenna's Products will be front and center. As well, Alphaderm's CEO, Irene Grimm has been added to the list of speakers. She will present several public presentations to the audience attending the exposition. The Collagenna Skin Care line to the participants will be showcased. Products will be available for purchase in the Alphaderm/Collagenna booth.

Michael Arnkvarn, CEO of Collagenna Skin Care Products stated, "We are very excited about the feedback that we have been receiving from the Swiss market. The products are giving the expected results and Alphaderm is ordering on a regular basis. In fact, they have hired an experienced skin representative who will be dedicated to the promotion of the Collagenna Skin Care line. This exposition will allow us to maintain the momentum that the initial sales efforts have created. Alphaderm's main market is with hotels, spas and skin care clinics but we both agree that we would entertain some distribution via retail outlets such as pharmacies and this will be an excellent opportunity to test the waters."

In other news Michael Arnkvarn, CEO of Collagenna Skin Care Products invites all shareholders and followers of HTDS to attend the company shareholder Expo in Toronto April 9th at the Marriott Airport hotel. Shortly the company will be making an update on its recently announced share buyback program and the progress made to date.

The company reminds our shareholders and followers that the company does not subscribe to the PinkSheets.Com Filing Service. Its IR company web site section "NEWS and FILING" TAB www.minamargroup.net should be reviewed by its followers for further updates on this and other business matters. Non-newsworthy events are not press released however posted on this separate support sites to keep our followers advised of day-to-day events, and the company corporate web site. For any matters relating to retail investor queries or to send us the company directly a message please click on the "INVESTOR SUPPORT" TAB or this direct link www.minamargroup.net/helpdesk.

To be included in company's email database for press releases, industry updates, and non-weekly activity at the company that may or may not be news released, please subscribe or opt in mailer at www.minamargroup.com/updates.

Safe Harbor Statement

Information in this filing may contain statements about future expectations, plans, prospects or performance of Hard to Treat Diseases, Inc. that constitute forward-looking statements for purposes of the safe harbor Provision's under the Private Securities Litigation Reform Act of 1995. The words or phrases "can be," "expects," "may affect," "believed," "estimate," "project," and similar words and phrases are intended to identify such forward-looking statements. HTDS Corporation cautions you that any forward-looking information provided by or on behalf of Hard to Treat Diseases, Inc. is not a guarantee of future performance. None of the information in this filing constitutes or is intended as an offer to sell securities or investment advice of any kind. Hard to Treat Diseases, Inc.'s actual results may differ materially from those anticipated in such forward-looking statements as a result of various important factors, some of which are beyond Hard to Treat Diseases, Inc.'s control. In addition to those discussed in Hard to Treat Diseases, Inc.'s press releases, public filings, and statements by Hard to Treat Diseases, Inc.'s management, including, but not limited to, Hard to Treat Diseases, Inc.'s estimate of the sufficiency of its existing capital resources, Hard to Treat Diseases, Inc.'s ability to raise additional capital to fund future operations, HTDS Corporation's ability to repay its existing indebtedness, the uncertainties involved in estimating market opportunities and, in identifying contracts which match Hard to Treat Diseases, Inc.'s capability to be awarded contracts. All such forward-looking statements are current only as of the date on which such statements were made. Hard to Treat Diseases, Inc. does not undertake any obligation to publicly update any forward-looking statement to reflect events or circumstances after the date on which any such statement is made or to reflect the occurrence of unanticipated events.

CONTACT: For medical and scientific dialogue inquiry only, please contact medicalinfo@htdsmedical.com; For any corporate matters, please contact www.minamargroup.com/helpdesk

SOURCE Hard to Treat Diseases
Advertisement


Advertisement

You May Also Like

Advertisement
View All

Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
User Avatar
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions
s
'SHIFTS: Beyond the Visible': New Collection Combi...
S
Labopharm completes licensing and distribution agr...